Tuesday brought a wave of downgrades across Wall Street, with analysts pumping the brakes on stocks ranging from cryptocurrency platforms to diagnostic testing companies. Sometimes the most interesting market signal isn't what analysts like—it's what they're backing away from.

Coinbase Loses Its Champion

The headline downgrade came from Argus Research analyst Kevin Heal, who moved Coinbase Global Inc (COIN) from Buy to Hold. With shares trading at $246.23 on Tuesday, Heal apparently sees the cryptocurrency exchange's rally losing steam. It's a notable shift for a stock that's been riding the crypto wave.

Medical Diagnostics Hit a Ceiling

Canaccord Genuity's Kyle Mikson delivered an interesting mixed message on Exact Sciences Corp (EXAS). He downgraded the stock from Buy to Hold, but simultaneously raised his price target from $85 to $105. With shares trading at $101.02, that math tells you everything: there's only about 4% upside left in his view. Sometimes a downgrade with a higher price target is the most honest call on Wall Street—it means the stock already got where it was going.

Biotech Retreat

D.A. Boral Capital analyst Jason Kolbert downgraded Invivyd Inc (IVVD) from Buy to Hold, with shares trading at $2.26 on Tuesday. The biotech sector has been a volatile ride lately, and Kolbert apparently decided this was a good time to step back.

Flying Cars Lose Altitude

JPMorgan's Beatrice Lam took a harsher view on EHang Holdings Ltd – ADR (EH), downgrading the Chinese autonomous aerial vehicle maker from Overweight to Neutral. More painful was the price target slash from $21 to $13. With shares at $13.46 on Tuesday, they're already trading right around that reduced target, suggesting Lam sees little room for upward movement in the near term.

Beauty Giant Faces Headwinds

The most bearish call came from Rothschild & Co analyst Kyriaki Koutta, who downgraded Estee Lauder Companies Inc (EL) from Neutral to Sell and cut the price target from $83 to $70. That's a fairly aggressive stance, implying significant downside from Tuesday's trading price of $93.09. When an analyst goes all the way to Sell rather than just Hold, they're really waving a red flag.

These downgrades represent a cross-section of market concerns—from crypto volatility to international manufacturing challenges to simply stocks that have already reached their near-term potential. Not every rating change means disaster, but they're worth watching as signals about where analyst confidence is shifting.